Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Interim Serum Soluble Interleukin-2 Receptor Levels Are Strongly Associated with Prognosis in Newly Diagnosis DLBCL Patients

Haruya Okamoto, MD, Akihiro Miyashita, MD, Hiroaki Nagata, MD, Yasuhiko Tsutsumi, MD PhD, Yuri Kamitsuji, MD PhD, Yutaka Kobayashi, MD PhD, Nobuhiko Uoshima, MD PhD

Blood (2019) 134 (Supplement_1): 4118.

https://doi.org/10.1182/blood-2019-122375

Published: 2019

Journal Articles

Retrospective Analysis Of The Recent Treatment Strategies For The Patients With Myeloma-Related Diseases Registered In Kansai Myeloma Forum

Blood (2013) 122 (21): 3385.

https://doi.org/10.1182/blood.V122.21.3385.3385

Published: 2013

Journal Articles

Automated and Rapid Detection of BCR-ABL Kinase Domain Mutations in IM Resistant Patients with Ph+ Leukemias.

Ruriko Tanaka, MMSc, Shinya Kimura, MD, PhD, Toshiya Hosomi, Mitsuharu Hirai, Rina Nagao, Asumi Yokota, MMSc, Yuri Kamitsuji, MD, PhD, Eri Kawata, MD, PhD, Hisayuki Yao, MD, Kazuki Sakai, MD, Hideyo Hirai, MD, PhD, Eishi Ashihara, MD, PhD, Souichi Adachi, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2590.

https://doi.org/10.1182/blood.V114.22.2590.2590

Published: 2009

Journal Articles

ß-Catenin siRNA Successfully Suppressed the Progression of Multiple Myeloma in In Vivo Mouse Model.

Eri Kawata, MD, Eishi Ashihara, MD, PhD, Ruriko Tanaka, Asumi Yokota, Yoshihide Murotani, MD, Miki Taniguchi, MD, Yuri Kamitsuji, MD, Junya Kuroda, MD, PhD, Tohru Inaba, MD, PhD, Chihiro Shimazaki, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD

Blood (2007) 110 (11): 2506.

https://doi.org/10.1182/blood.V110.11.2506.2506

Published: 2007

Journal Articles

Kinetics of Circulating Endothelial Progenitors in Patients with Sclerodermatous Chronic Graft-Versus-Host Disease.

Eishi Ashihara, MD, PhD, Kazuho Shimura, MD, Chihiro Shimazaki, MD, PhD, Shinsaku Matsunaga, MD, Ruriko Tanaka, Asumi Yokota, Yoshihide Murotani, MD, Miki Takeuchi, MD, Eri Kawata, MD, Yuri Kamitsuji, MD, Junya Kuroda, MD, PhD, Masafumi Taniwaki, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD

Blood (2007) 110 (11): 1078.

https://doi.org/10.1182/blood.V110.11.1078.1078

Published: 2007

Journal Articles

ABT-737 Is a Useful Component of Combinatory Chemotherapies for Chronic Myelogenous Leukemias with Diverse Drug Resistance Mechanisms.

Junya Kuroda, MD, PhD, Shinya Kimura, MD, PhD, Michael Andreeff, Eishi Ashihara, MD, PhD, Yuri Kamitsuji, MD, Andreas Strasser, Masafumi Taniwaki, Taira Maekawa

Blood (2007) 110 (11): 808.

https://doi.org/10.1182/blood.V110.11.808.808

Published: 2007

Journal Articles

The Bcr-Abl Kinase Inhibitor INNO-406 Induces Autophagy and Different Modes of Cell Death Execution in Bcr-Abl-Positive Leukemias.

Yuri Kamitsuji, MD, Junya Kuroda, PhD, Shinya Kimura, PhD, Ken-ichiro Watanabe, PhD, Eishi Ashihara, PhD, Yoshihiro Yui, MD, Motonobu Watanabe, MD, Hiroshi Matsubara, MD, Yasuhiro Mizushima, MD, Yoshimi Hiraumi, MD, Hideo Tanaka, PhD, Eri Kawata, MD, Taira Maekawa, MD, Tatsutoshi Nakahata, PhD, Souichi Adachi, PhD

Blood (2007) 110 (11): 2951.

https://doi.org/10.1182/blood.V110.11.2951.2951

Published: 2007

Journal Articles

The Significance of BAALC Expression and CEBPa Mutations as New Prognostic Factors in Pediatric Acute Myeloid Leukemia with Normal Karyotype.

Yasuhiro Mizushima, Souichi Adachi, Tomohiko Taki, Akira Shimada, Yasuhide Hayashi, Ichiro Tsukimoto, Masahiro Yui, Yuri Kamitsuji, Yoshimi Hiraumi, Hiroshi Matsubara, Motonobu Watanabe, Ken-ichiro Watanabe, Tatsutoshi Nakahata

Blood (2006) 108 (11): 2279.

https://doi.org/10.1182/blood.V108.11.2279.2279

Published: 2006

Journal Articles

Cell Death Mechanisms Induced by INNO-406, a Novel Tyrosine Kinase Inhibitor for Imatinib-Resistant Ph+ Leukemia.

Yuri Kamitsuji, MD, Souichi Adachi, MD, PhD, Motonobu Watanabe, MD, Hiroshi Matsubara, MD, Yasuhiro Mizushima, MD, Yoshimi Hiraumi, MD, Ken-Ichiro Watanabe, MD, PhD, Hideo Tanaka, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, Tatsutoshi Nakahata, MD, PhD

Blood (2006) 108 (11): 2177.

https://doi.org/10.1182/blood.V108.11.2177.2177

Published: 2006

Journal Articles

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Junya Kuroda, Kiyoshi Sato, Yuri Kamitsuji, Eri Kawata, Yasuyuki Deguchi, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa

Blood (2006) 109 (1): 306–314.

https://doi.org/10.1182/blood-2006-03-013250

Published: 2006

Includes: Supplemental data

Journal Articles

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Shinya Kimura, Haruna Naito, Hidekazu Segawa, Junya Kuroda, Takeshi Yuasa, Kiyoshi Sato, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Kimio Nasu, Tetsuo Asaki, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa

Blood (2005) 106 (12): 3948–3954.

https://doi.org/10.1182/blood-2005-06-2209

Published: 2005

Journal Articles

A Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, NS-187, Is a Novel Agent for Imatinib-Resistant Leukemia.

Shinya Kimura, MD, Haruna Naito, PhD, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, MD, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Tetsuo Asaki, Tomoko Niwa, PhD, Kazuko Hirabayashi, PhD, Taira Maekawa, MD

Blood (2005) 106 (11): 1522.

https://doi.org/10.1182/blood.V106.11.1522.1522

Published: 2005

NARROW

Interim Serum Soluble Interleukin-2 Receptor Levels Are Strongly Associated with Prognosis in Newly Diagnosis DLBCL Patients

Retrospective Analysis Of The Recent Treatment Strategies For The Patients With Myeloma-Related Diseases Registered In Kansai Myeloma Forum

Automated and Rapid Detection of BCR-ABL Kinase Domain Mutations in IM Resistant Patients with Ph+ Leukemias.

ß-Catenin siRNA Successfully Suppressed the Progression of Multiple Myeloma in In Vivo Mouse Model.

Kinetics of Circulating Endothelial Progenitors in Patients with Sclerodermatous Chronic Graft-Versus-Host Disease.

ABT-737 Is a Useful Component of Combinatory Chemotherapies for Chronic Myelogenous Leukemias with Diverse Drug Resistance Mechanisms.

The Bcr-Abl Kinase Inhibitor INNO-406 Induces Autophagy and Different Modes of Cell Death Execution in Bcr-Abl-Positive Leukemias.

The Significance of BAALC Expression and CEBPa Mutations as New Prognostic Factors in Pediatric Acute Myeloid Leukemia with Normal Karyotype.

Cell Death Mechanisms Induced by INNO-406, a Novel Tyrosine Kinase Inhibitor for Imatinib-Resistant Ph+ Leukemia.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

A Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, NS-187, Is a Novel Agent for Imatinib-Resistant Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only